Mediolanum International Funds’s Royalty Pharma RPRX Stock Holding History

Mediolanum International Funds’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Sell	21,656 -157	-0.7%	-$8.17K	0.01%	398
2026 Q1	$1.01M	Sell	21,813 -40,296	-65%	-$1.76M	0.01%	390
2025 Q4	$2.42M	Sell	62,109 -606	-1%	-$23.1K	0.02%	337
2025 Q3	$2.21M	Buy	62,715 +6,697	+12%	+$242K	0.02%	337
2025 Q2	$2.01M	Sell	56,018 -75,430	-57%	-$2.5M	0.02%	333
2025 Q1	$4.12M	Sell	131,448 -8,894	-6%	-$282K	0.06%	272
2024 Q4	$3.54M	Sell	140,342 -125,230	-47%	-$3.32M	0.05%	273
2024 Q3	$7.48M	Sell	265,572 -11,007	-4%	-$305K	0.1%	196
2024 Q2	$6.89M	Buy	276,579 +26,072	+10%	+$723K	0.11%	177
2024 Q1	$7.63M	Buy	+250,507	New	+$7.38M	0.12%	181

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mediolanum International Funds's RPRX Position: Q2 2026 in Review

Mediolanum International Funds reduced its Royalty Pharma (RPRX) stake by 0.72% in Q2 2026, selling an estimated $8.17K and leaving 21,656 shares worth $1.24M. The position accounts for 0.01% of the portfolio, ranked #398.

Mediolanum International Funds first reported a position in RPRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.63M in Q1 2024. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Mediolanum International Funds held 21,656 shares of Royalty Pharma worth $1.24M as of Q2 2026.
Mediolanum International Funds sold 157 Royalty Pharma shares in Q2 2026, an estimated $8.17K.
Royalty Pharma made up 0.01% of Mediolanum International Funds's portfolio in Q2 2026, its #398 holding.
Mediolanum International Funds first reported a position in Royalty Pharma in Q1 2024 and has held it in 10 quarters since.
Mediolanum International Funds's Royalty Pharma position peaked at $7.63M in Q1 2024.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Mediolanum International Funds's 13F filing for Q2 2026, filed 23 Jul 2026.